Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Mandatory HPV Vaccination Should Be Paired With Opt-Out Option, Says Study

XTALKS VITALS NEWS

There are currently two vaccines available – Merck’s Gardasil and GlaxoSmithKline’s Cervarix – which protect against the most common strains of the virus.

Tweetables from this article:

Tweet: Studies found that 21% of parents with children aged 11 to 17 were in favor of a law requiring HPV vaccination. http://buff.ly/2bIETC7"Studies found that 21% of parents with children aged 11 to 17 were in favor of a law requiring HPV vaccination."

Share this!

September 8, 2016 | by Sarah Massey, M.Sc.

Requiring children to get vaccinated against the sexually-transmitted human papillomavirus (HPV) has been a controversial issue among parents and politicians. As such, a new study suggests that most parents would only be in favour of mandatory vaccination if they were provided with an opt-out option.

HPV has been implicated in multiple cases of cervical cancer, along with a number of other types of the disease. There are currently two vaccines available – Merck’s Gardasil and GlaxoSmithKline’s Cervarix – which protect against the most common strains of the virus.

Merck’s Gardasil protects against HPV strains 6, 11, 16 and 18, While GlaxoSmithKline’s Cervarix only protects against types 16 and 18. These strains are responsible for approximately 70 percent of cervical cancer cases, and numerous other types of anal, vulvar, vaginal and penile cancer.

Gardasil brought in almost $2 billion in sales in 2015, making it one of Merck’s best-selling drugs. Despite its high sales numbers, the vaccine has faced considerable pushback from religious groups.

The vaccines are mainly targeted toward adolescent girls, who could be protected against HPV infection before they become sexually active. In 2014, about 40 percent of young girls in the US were given all three doses of the HPV vaccine, according to the Centers for Disease Control and Prevention (CDC).



The number of girls vaccinated that year was up from 38 percent in 2013. More young boys are also receiving the HPV vaccine, with 22 percent being vaccinated in 2014 compared to only 13 percent in 2013. Of course, more children would be vaccinated if the shot were required by law.

To assess the popularity of this idea, researchers at the University of North Carolina at Chapel Hill conducted a national study involving 1,501 parents. They found that 21 percent of parents with children aged 11 to 17 were in favour of a law requiring HPV vaccination. Interestingly, if an opt-out option was included, 57 percent of parents thought the law would be a good idea.

“School entry requirements are highly acceptable to parents, but only when implemented in a way that makes them ineffective,” said study author Noel T. Brewer, Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina. “Opt-outs lead to a large number of parents choosing not to vaccinate their children, and that makes requirements ineffective in raising vaccination rates.”


Keywords: Vaccination, Cancer


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News


CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.